Assignee
SUMITOMO PHARMA AMERICA INC
US·2 granted patents·19 pending applications·0 citations·filing 2021–2025
Top patents by PatentIndex Score
21 records- 0191US2026034093A1Multicyclic compounds and methods of use thereofSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 0285US2024358675A1Multicyclic compounds and methods of use thereofSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 0384US2025129085A1Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitorsSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 0481US2024409550A1Compounds and compositions and uses thereofSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 0579US2024083855A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO PHARMA AMERICA INC·Filed 2023·Application pending·0 cites
- 0679US2026035381A1Compounds and compositions and uses thereofSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 0775US2024425516A1Salts, crystal forms, and production methods thereofSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 0873US2024350453A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 0972US11987591B2Salts, crystal forms, and production methods thereofSUMITOMO PHARMA AMERICA INC·Filed 2022·Granted May 21, 2024·0 cites·21 claims
- 1072US2025302800A1Methods of treating social function disordersSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1172US2025082634A1Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancerSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1271US2025320217A1Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitorsSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 1370US11958862B2Compounds and compositions and uses thereofSUMITOMO PHARMA AMERICA INC·Filed 2021·Granted Apr 16, 2024·0 cites·34 claims
- 1470US2025057806A1Methods of treating schizophreniaSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1569US2024417382A1Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereofSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1663US2025312308A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 1760US2024366559A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 1855US2024158416A1Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disordersSUMITOMO PHARMA AMERICA INC·Filed 2022·Application pending·0 cites
- 1955US2024182436A1Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereofSUMITOMO PHARMA AMERICA INC·Filed 2022·Application pending·0 cites
- 2053US2025262185A1Methods of administering neuropsychiatric medications based on renal impairmentSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 2144US2025270231A1Ulotaront hydrochloride manufacturing processSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SUMITOMO PHARMA AMERICA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →